C4XD acquire new drug discovery technologies

Drug discovery and development company C4X Discovery Holdings (C4XD) announced on Tuesday the acquisition of advanced drug discovery technologies from MolPlex Technologies.

Molplex Technologies have developed a pioneering software-based system that combines state-of-the art chemoinformatics, computational chemistry and artificial intelligence to optimise the drug development process.

C4XD was founded in 2008 as a spin out from the University of Manchester. The firm has two software platforms Taxonomy3® and Conformetrix that provide a “significant competitive advantage”. Conformetrix is the only technology in the world that can use experimentally-determined solution-structures to design drug molecules that are optimally shaped to provide potency and selectivity.

The MolPlex Technologies, originally developed at Newcastle University, will complement this by predicting whether the resulting molecules have the “druggable” qualities required for humans. The board believe this will “reduce the cost, time and attrition associated with early development and increasing the likelihood of eventual clinical success.”

CEO of C4X Discovery, Dr Clive Dix said: "These new technologies…add to our ability to capitalise on the identification of high-value targets from our Taxonomy3® technology to generate drug candidates with greater clinical and commercial differentiation. We are rapidly building an internal pipeline of exciting therapeutic programmes and moving steadily towards realising our goal of becoming the world's most productive drug discovery and development company."